Double-Blind Placebo-Controlled Pilot Investigation of the Safety of a Single Dose of Rapid-Acting Intranasal Insulin in Down Syndrome

BACKGROUND: Individuals with Down syndrome are likely to develop clinical and neuropathological brain changes resembling Alzheimer’s disease dementia by the ages of 35–40 years. Intranasal insulin is a potential treatment for neurodegenerative disease that has been shown to reduce amyloid plaque bur...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenbloom, Michael, Barclay, Terry, Johnsen, Justin, Erickson, Lauren, Svitak, Aleta, Pyle, Maria, Frey, William, Hanson, Leah R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067723/
https://www.ncbi.nlm.nih.gov/pubmed/32077057
http://dx.doi.org/10.1007/s40268-020-00296-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067723/
https://www.ncbi.nlm.nih.gov/pubmed/32077057
http://dx.doi.org/10.1007/s40268-020-00296-2

Ejemplares similares